RGD-4C is a double cyclic peptide that can bind preferentially to integrins at sites of tumor angiogenesis and inflamed synovium in vivo, and can be internalized into targeted cells. Novel applications include the coupling of RGD-4C to proapoptotic domains to treat tumors and inflammatory arthritis, and to radioactive labels for the broad spectrum imaging of tumor tissue.